February 3, 2022
The MMA’s next noon-time forum will examine sodium-glucose cotransporter-2 (SGLT2) inhibitors, a new 'triple play' for diabetes, cardiovascular and kidney diseases. The forum will take place February 9 from noon to 1 p.m.
This forum will review the pharmacology of SGLT2 inhibitors and then discuss the role these drugs play in the management of type 2 diabetes. The evidence for improving cardiorenal outcomes will be presented and recommendations made for the use of these drugs in patients with cardiovascular or renal diseases. The session will conclude with a Q&A panel discussion.
The forum will be moderated by Andrew Olson, MD, and include Anne Bantle, MD, Prabhjot S. Nijjar, MD, and Mark Rosenberg, MD. All faculty for this forum are with the University of Minnesota Medical School.
Learning objectives for the forum include:
Describe the pharmacology of SGLT2 inhibitors and the use of these drugs in the management of type 2 diabetes mellitus.
Appraise the data supporting the cardiorenal protective effects of SGLT2 inhibitors.
Utilize SGLT2 inhibitors in the management of patients with diabetes, cardiovascular or kidney diseases.
To register, click here.
The forum is free to members, $15 for non-members. This forum is being held in partnership with the University of Minnesota.
July 10, 2025
With the passage of President Trump’s budget bill, many in healthcare are wondering how it will affect the practice of medicine in the United States, and how it will impact the health of Minnesotans.
July 10, 2025
With an overwhelming 90% vote of support, Allina Health physicians, physicians’ assistants, and nurse practitioners voted to authorize a strike if the members of the Doctors Council – SEIU and Allina cannot reach a deal.
July 10, 2025
The Minnesota Department of Health’s (MDH) Equitable Health Care Task Force is seeking public comment on its draft recommendations for improving health equity across the state.